| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 updated data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Phase 1/2 updated data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Phase 1/2 updated data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Passage Bio, Inc.$4.57
-0.14 (-2.97%)
D 21Pipeline Score Overvalued Biotech · Commercial
Market Cap
16.76 M
EPS
-11.84
P/E Ratio
-
Value Trade
206.62 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.09 M
Operating CF
-12.99 M
Total Assets
36.46 M
Total Liabilities
24.71 M
Equity
11.75 M
D/E Ratio
12,345
0.29 %
Week
-14.48 %
1 Month
-45 %
3 Month
-28.33 %
6 Month
-97.99 %
5 Year
-98.83 %
All Time
Cash Data
Cash Position
33.34 M
Monthly Burn
4.33 M
Runway
6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
39.62 K
52 Week Range
3.94 - 20
% held by Insiders
7.74 %
% held by Institutions
56.96 %
Enterprise Value
-10.82 M
Total Shares
3.21 M
Short %
4.02 %
Float Shares
2.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Passage Bio, Inc.
381Total events
2Upcoming
74Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 2
Event history 379
Q3 2026
●Development Candidate NominationPreclinical
Declare clinical candidate for Huntington's disease
Huntington's diseasesource ↗
Jun 24, 2026
Jun 24, 2026
▼Equity OfferingCorporate
Concurrent oversubscribed $100 million private placement financing for Remix
Apr 20, 2026
▲Full ResultsPBFT02Clinical Data
Updated interim data from upliFT-D trial showing improvements in biomarkers
frontotemporal dementia with GRN mutationssource ↗
Apr 20, 2026
●Type C MeetingPBFT02FDA Meeting
Completed Type C meeting with FDA regarding registrational trial design
frontotemporal dementia with GRN mutationssource ↗
Apr 20, 2026
▼FDA Feedback ReceivedPBFT02FDA Meeting
FDA feedback from Type C meeting: randomized controlled trial required
frontotemporal dementia with GRN mutationssource ↗
Apr 20, 2026
◆Pipeline PrioritizationPBFT02Corporate
Evaluating potential next steps for PBFT02 clinical development program
frontotemporal dementia with GRN mutationssource ↗
Apr 20, 2026
Mar 4, 2026
Mar 3, 2026
Drug Pipeline Intelligence
D21
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 19%
Micro Cap (rank 739 of 911)
Percentile RankPassage Bio, Inc. faces pipeline headwinds (21/100), with $208M risk-adjusted pipeline value, led by PBFT02 in Frontotemporal Dementia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBFT02 Small molecule | Frontotemporal Dementia | Phase 1 | NCT04747431 | 5% | $208M | ACTIVE NOT_RECRUITING | 30 | STALLED | D (35) | Aug 1, 2031 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PBFT02 | frontotemporal dementia with granulin mutations | Phase 1/2 | 2026-04-20 | whole brain atrophy reduction: 64%; atrophy at 12 months treated: 3.1%; atrophy at 12 months natural history: 8.7% Read More | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates Read More | |
PBFT02 | frontotemporal dementia with granulin mutations | Phase 1/2 | 2026-04-20 | whole brain atrophy reduction: 64%; atrophy at 12 months treated: 3.1%; atrophy at 12 months natural history: 8.7% Read More | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates Read More | |
PBFT02 | frontotemporal dementia with granulin mutations | Phase 1/2 | 2026-04-20 | whole brain atrophy reduction: 64%; atrophy at 12 months treated: 3.1%; atrophy at 12 months natural history: 8.7% Read More | Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PASG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PASG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PASG▼ -26.4%on this news
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio and Remix Therapeutics have announced a merger agreement to form a new entity focused on RNA processing therapies. The combined company will operate under the name Remix Therapeutics and aims to advance its lead program, REM-422, targeting MYB in various cancers. A concurrent $100 million financing is expected to fund operations through 2028, supporting key clinical milestones. The merger is anticipated to close in Q4 2026, subject to regulatory approvals.
Read more →PASG▼ -46.4%on this news
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Passage Bio reported positive interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing improvements in biomarkers of frontotemporal dementia with granulin mutations. However, the FDA has mandated a randomized controlled trial for further development, presenting challenges for the company. Passage Bio is also undergoing a strategic review to enhance shareholder value.
Read more →PASG▼ -8.9%on this news
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported its financial results for Q4 and full year 2025, highlighting progress in its clinical programs for frontotemporal dementia and Huntington's disease. The company successfully enrolled patients in its upliFT-D study and plans to report interim data and seek regulatory feedback in 2026. Despite a net loss, the company maintains a cash runway through Q1 2027.
Read more →PASGPassage Bio to Participate in Upcoming Investor Conferences
Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. The company's management will give presentations and participate in investor meetings on February 26, 2026, and March 4, 2026, respectively, in Boston, MA. Passage Bio focuses on therapies for neurodegenerative diseases, particularly their lead candidate PBFT02, aimed at enhancing progranulin levels to slow disease progression.
Read more →PASG▲ +10.3%on this news· ran to +73% by day 3
Passage Bio. All rights reserved. Corporate Presentation Redefining the Course of Neurodegenerative Conditions January 2026 Forward - Looking Statement This presentation includes "forward - looking statements" within the
Passage Bio has presented forward-looking statements regarding the development of its gene therapy candidate, PBFT02, aimed at treating Frontotemporal Dementia (FTD) caused by GRN mutations. The company highlighted potential benefits, including promising early clinical trial data and regulatory designations that position PBFT02 as a leading therapy in its class. However, the company acknowledged various risks associated with regulatory approvals, clinical trial management, and dependencies on external collaborators. Overall, Passage Bio aims to redefine treatment for neurodegenerative conditions while maintaining financial stability through expected cash reserves.
Read more →PASG▲ +14.8%on this news· ran to +40% by day 1
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported its third quarter 2025 financial results, highlighting active enrollment in new patient cohorts for its upliFT-D study. The company has successfully aligned with the FDA on its PBFT02 manufacturing process and is on track to receive regulatory feedback on trial design in the first half of 2026. Passage Bio's cash runway extends into the first quarter of 2027, supporting ongoing clinical efforts.
Read more →PASGPassage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio, a clinical stage genetic medicines company, will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 12, 2025. CEO Will Chou will participate in a fireside chat, which will also be available via live webcast. The company focuses on developing therapies for neurodegenerative diseases, particularly through its lead candidate PBFT02.
Read more →PASGPassage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
Passage Bio, Inc. will participate in the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025. CEO Will Chou will be part of a panel discussion in New York City. The event will be webcast live, with a replay available for 90 days. Passage Bio is focused on developing therapies for neurodegenerative diseases.
Read more →PASGPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Passage Bio, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Will Chou will present an overview of the company and engage in one-on-one meetings with investors. A video webcast of the presentation will be available for registered attendees, emphasizing the company's focus on advancing therapies for neurodegenerative diseases.
Read more →PASGPASSAGE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demo
Passage Bio reported its financial results for the second quarter of 2025, highlighting significant progress in its upliFT-D clinical trial. The company completed dosing for Cohort 2 and reported encouraging interim data on PBFT02, which shows improved biomarkers for neurodegeneration. Passage Bio's financial position appears stable with a cash runway projected to extend through early 2027. Management anticipates further enrollment in upcoming cohorts as they continue to engage with health authorities on future regulatory pathways.
Read more →PASG▼ -9.9%on this news· ran to -32% by day 3
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio has announced a 1-for-20 reverse stock split, effective July 14, 2025, to comply with Nasdaq's minimum bid price requirement. This decision was approved by stockholders during the 2025 annual meeting. The reverse stock split will reduce the number of outstanding shares significantly, but will not affect stockholders' percentage ownership interests.
Read more →PASG▼ -14.4%on this news
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Passage Bio reported promising interim data from the Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia. The treatment demonstrated significant increases in cerebrospinal fluid progranulin levels and improvements in plasma neurofilament, indicating potential benefits for patients. The company plans to amend the trial protocol to enhance safety and broaden patient eligibility, with regulatory feedback anticipated in early 2026.
Read more →PASGPASSAGE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated f
Passage Bio, Inc. has reported its first quarter financial results for 2025, highlighting key achievements in its ongoing clinical trials. The company has successfully treated its first patient with Dose 2 of PBFT02 and has enrolled a second patient, with more patients being evaluated. They also announced advancements in a high productivity manufacturing process for PBFT02, which was presented at a prominent industry meeting. Financially, Passage Bio indicates a cash runway that extends into the first quarter of 2027, reflecting its ongoing operational stability and commitment to developing therapies for neurodegenerative diseases.
Read more →PASG▼ -11.4%on this news
PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in p
Passage Bio reported its fourth quarter and full-year financial results for 2024, demonstrating progress in its PBFT02 program. Interim data indicate positive outcomes, including elevated CSF PGRN levels and reduced plasma NfL levels, suggesting potential benefits in treating neurodegenerative diseases for FTD-GRN patients. The company has successfully developed a high-productivity manufacturing process and aims for continued enrollment in clinical trials. Passage Bio's cash runway has been extended into the first quarter of 2027, positioning the company well for future developments.
Read more →PASGPASSAGE BIO ANNOUNCES INTERIM DATA FROM UPLIFT-D STUDY IN FTD- GRN AND PROVIDES BUSINESS UPDATES PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progr
Passage Bio announced interim data from its ongoing Phase 1/2 upliFT-D clinical trial evaluating the gene therapy PBFT02 for patients with frontotemporal dementia (FTD) associated with granulin mutations. The data indicated a significant increase in cerebrospinal fluid (CSF) PGRN levels and suggested potential reductions in plasma NfL levels, which correlate with disease progression. The company also revealed plans to transition to an outsourced testing model, extending its financial runway through Q1 2027, while ongoing trials continue to assess safety and efficacy.
Read more →PASG▼ -12.9%on this news· ran to -29% by day 3
PASSAGE BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohor
Passage Bio reported its financial results for the third quarter of 2024, highlighting advancements in its PBFT02 gene therapy program. During the quarter, the company enrolled four patients in the upliFT-D trial for FTD-GRN, with dosing on schedule. Updated interim data from the ongoing trial indicated the therapy was well-tolerated and effectively raised CSF progranulin levels. The company maintains a robust cash position, ensuring operational continuity into mid-2026 amidst ongoing challenges in clinical trials and regulatory pathways.
Read more →PASGPassage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio, a clinical stage genetic medicines company, announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024. CEO Will Chou, M.D. will deliver a presentation about the company's focus on advancing therapies for neurodegenerative diseases. The company's lead candidate, PBFT02, aims to treat conditions like frontotemporal dementia. A live webcast of the presentation will be available on their website, along with a 30-day replay afterwards.
Read more →PASG▲ +11.4%on this news
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31 st Annual Conference Preclinical data demonstrated that an AAV1 vector achieved s
Passage Bio presented positive preclinical and interim clinical data for its gene therapy PBFT02 at the ESGCT Annual Conference. The AAV1 vector demonstrated superior elevation of human progranulin levels compared to other vectors. The therapy showed promising results in improving lysosomal function and reducing neuroinflammation in preclinical models, as well as a good safety profile in ongoing clinical trials. These findings position PBFT02 as a potentially best-in-class therapy for frontotemporal dementia with GRN mutations.
Read more →PASG▼ -5.1%on this news
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Passage Bio, a clinical stage genetic medicines company, announced that its CEO, Dr. Will Chou, will present at Chardan’s 8th Annual Genetic Medicines Conference on October 1, 2024. The company focuses on developing therapies for neurodegenerative diseases, with its lead product candidate, PBFT02, targeting conditions like frontotemporal dementia. A live webcast of the presentation will be available, along with a replay for 30 days afterwards. This event highlights the company's commitment to advancing treatment options in the genetic medicine arena.
Read more →PASG▼ -9.4%on this news
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) Interim safety and biomarker data from the upliF
Passage Bio is set to present positive interim data from their upliFT-D clinical trial evaluating PBFT02, a gene therapy for frontotemporal dementia with GRN mutations, at the ISFTD2024 conference. The trial data indicates that Dose 1 of PBFT02 resulted in significant and sustainable elevation of CSF progranulin levels over 12 months. Furthermore, the treatment was well-tolerated among the five patients in the first cohort, showing no serious adverse events. The company aims to advance its strategy by exploring PBFT02's impact on other neurodegenerative diseases.
Read more →PASG▲ +6.1%on this news
Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio has announced the appointment of Tom Kassberg to its Board of Directors and the Audit Committee. Kassberg, currently the Chief Business Officer at Ultragenyx, brings extensive experience in biotech and corporate development. His expertise will be instrumental as Passage Bio advances its lead product candidate, PBFT02, aimed at treating neurodegenerative diseases. The company emphasized its commitment to improving patient lives through innovative therapies.
Read more →PASG▼ -6%on this news
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Passage Bio, Inc. announced that its CEO, Will Chou, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The company is dedicated to developing one-time therapies for neurodegenerative diseases, with its lead product candidate, PBFT02, targeting frontotemporal dementia. A webcast of the presentation will be available live and for 30 days afterward on their website. This participation underscores Passage Bio's commitment to investor engagement and advancing its mission in genetic medicines.
Read more →PASG▼ -5.2%on this news
PASSAGE BIO REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort
Passage Bio reported its financial results for Q2 2024, highlighting the successful enrollment of the first patient in Cohort 2 of the upliFT-D trial. The company has achieved alignment with the FDA to expand its clinical development plans and plans to present updated safety and biomarker data in September 2024. Despite these advancements, Passage Bio posted a net loss of $15,991, which raised concerns about its financial stability. The company, however, maintains a strong cash position with funding extended until mid-2026.
Read more →PASG▲ +6.6%on this newsshared move
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM
Passage Bio has out-licensed three pediatric gene therapy programs to GEMMA Biotherapeutics, allowing GEMMA exclusive rights for their development and commercialization. The agreement is aimed at facilitating the advancement of genetic therapies for diseases like GM1 gangliosidosis and Krabbe disease while Passage Bio refocuses on its lead asset, PBFT02. Furthermore, a new research collaboration with GEMMA is set to explore CNS disease therapies, extending Passage Bio's cash runway to the end of Q2 2026. This strategic move could enhance both companies' capabilities in addressing underserved patient populations.
Read more →PASGPassage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD- C9orf72 Patients Agency feedback from Type C meeting process supports the company s proposed clinical development
Passage Bio has received positive feedback from the FDA regarding the expansion of its upliFT-D trial to include patients with FTD-C9orf72 gene mutations. This feedback stems from the company's Type C meeting with the FDA, which supports their plans to evaluate the PBFT02 treatment in this patient population. The firm anticipates submitting a revised trial protocol and beginning patient dosing in the first half of 2025. The move is seen as critical for improving access to innovative treatments for patients with limited clinical trial options.
Read more →PASGPassage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Passage Bio, Inc. will be presenting at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. The presentation will be led by CEO William Chou and will emphasize the company's commitment to developing genetic medicines for neurodegenerative diseases. Their lead product candidate, PBFT02, aims to treat frontotemporal dementia by restoring lysosomal function. A live webcast of the event will be available online, along with a replay afterwards.
Read more →PASGPassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
Passage Bio, Inc. has awarded the third annual Tachi Yamada Scholarship to Carrie Gordon, a sophomore at Drexel University, for her outstanding academic achievements and commitment to medicine. The scholarship, honoring the legacy of Dr. Tachi Yamada, aims to support students pursuing careers in life sciences. In addition to financial assistance, the scholarship includes mentorship opportunities from Passage Bio. Gordon's dedication to the healthcare field and her involvement in research and community service were key factors in her selection as the recipient.
Read more →PASG▼ -10.5%on this news
PASSAGE BIO REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CS
Passage Bio, Inc. reported its financial results for the first quarter of 2024, highlighting promising developments in its upliFT-D clinical trial for PBFT02. Interim data showcased a consistent elevation in CSF progranulin levels in patients, indicating potential effectiveness of the treatment for neurodegenerative diseases. The company has successfully completed dosing in the first cohort of the trial and anticipates delivering significant data in the coming year. Despite a net loss of $16.7 million, there is optimism about the future progress of their lead therapy.
Read more →PASGPassage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Passage Bio, Inc. announced its participation in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 29, 2024. William Chou, M.D. and Eden Fucci will lead a virtual fireside chat to discuss the company’s advancements in genetic medicines targeting neurodegenerative diseases. The event aims to highlight the development of Passage Bio’s lead product candidate, PBFT02, which seeks to elevate progranulin levels in order to address the challenges posed by frontotemporal dementia. A live webcast will be accessible to investors and the media, reinforcing the company's commitment to innovation in healthcare.
Read more →PASGPassage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
Passage Bio has opened applications for its third annual Tachi Yamada Scholarship Program, aimed at supporting life science students at Pennsylvania colleges. The scholarship will grant $10,000 over two years to a sophomore student transitioning to junior status in fall 2024. Named in memory of Dr. Tachi Yamada, the program emphasizes the company's dedication to nurturing future scientists through financial assistance and mentorship opportunities.
Read more →PASGPASSAGE BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (F
Passage Bio reported its financial results for Q4 and the full year of 2023, highlighting significant milestones in its clinical development programs. The company is seeing promising data from its PBFT02 candidate in treating frontotemporal dementia, with plans to activate more clinical trial sites, including in Europe. Despite a reported net loss, the leadership expressed optimism about advancing PBFT02 into new indications for neurodegenerative diseases, anticipating a catalyst-rich year ahead.
Read more →PASGPassage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Passage Bio, Inc. will have its CEO, Dr. William Chou, participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will include a live webcast and will be available for replay after its conclusion. The company is known for developing one-time genetic therapies aimed at treating neurodegenerative diseases, with their lead product candidate, PBFT02, targeting frontotemporal dementia through the elevation of progranulin levels.
Read more →PASGNasdaq: PASG © 2024 Passage Bio. All rights reserved. Corporate Presentation January 2024 2 Forward-Looking Statement This presentation includes “forward-looking statements” within the meaning of, and
Passage Bio is advancing its gene therapy program PBFT02 aimed at treating neurodegenerative diseases by targeting progranulin levels in cerebrospinal fluid (CSF). Recent clinical data shows a significant increase in CSF progranulin post-treatment, which may alleviate associated pathologies. The company maintains a robust financial position, projected to support its initiatives through Q4 2025, while preparing to initiate dosing of new patient cohorts in the first half of 2024. However, previous doses raised concerns over acute immune responses in some patients, necessitating protocol amendments.
Read more →PASG▲ +7.4%on this news· ran to +26% by day 3
PASSAGE BIO ANNOUNCES PROMISING INITIAL DATA FROM PHASE 1/2 CLINICAL TRIAL OF PBFT02 IN FTD-GRN AND UPDATED STRATEGIC PRIORITIES Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first thre
Passage Bio announced promising initial data from its Phase 1/2 trial of PBFT02 for frontotemporal dementia with GRN mutations. The treatment achieved supraphysiologic levels of cerebrospinal fluid progranulin in the first three patients, with these elevated levels sustained for up to six months. The company has outlined strategic priorities to further develop PBFT02 and pursue its application in additional neurodegenerative diseases. Management is optimistic about the therapy's potential and indicated plans for future clinical development.
Read more →PASG▲ +6.1%on this news
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE TARA M. WILLIAMS, derivatively on behalf of PASSAGE BIO, INC. , Plaintiff, v. MAXIME GOWEN, ATHENA COUNTOURIOTIS, SANDIP KAPADIA, SAQIB ISLAM, THOMAS WOIWODE, LIAM RATCLI
Tara M. Williams has filed a stockholder derivative action against several defendants on behalf of Passage Bio, Inc. regarding claims of excessive compensation. A proposed settlement has been reached, subject to court approval, with the Settlement Hearing scheduled for March 4, 2024. The settlement includes corporate governance reforms and the potential dismissal of the action with prejudice. Stockholders are advised of their rights to participate in the hearing and to voice any objections regarding the settlement terms.
Read more →PASGPassage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Passage Bio, Inc. has announced the granting of an inducement award to a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The company provided options to purchase 10,400 shares of common stock at an exercise price equal to its closing stock price on the grant date. The options will vest over four years and are a strategic move to enhance the company's ability to attract and retain talent in pursuit of its mission to develop therapies for CNS disorders.
Read more →PASGPASSAGE BIO REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PB
Passage Bio, Inc. reported its third quarter 2023 financial results and highlighted recent progress in its clinical programs. The company is advancing its lead programs in neurodegenerative conditions and expects to present initial safety and biomarker data from its ongoing trial soon. Financially, the organization continues to face challenges with significant net losses, but remains optimistic about upcoming clinical data and collaborations to enhance its gene therapy pipeline. The company maintains a strong financial position during its critical growth phase.
Read more →PASG▲ +6.9%on this news
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
Passage Bio, Inc. will participate in Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on November 6, 2023. CEO William Chou will engage in a fireside chat during the event. The company, which specializes in genetic therapies for central nervous system disorders, has ongoing clinical programs targeting diseases such as GM1 gangliosidosis and frontotemporal dementia. Their collaboration with the University of Pennsylvania enhances their capabilities in gene therapy development.
Read more →PASGPassage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio, Inc. announced the granting of stock options to new employees as part of their inductions in accordance with Nasdaq Listing Rule 5635(c)(4). The options, totaling 50,000 shares at an exercise price equal to the company's closing stock price, are part of an effort to attract talent. Passage Bio is a clinical-stage company dedicated to developing therapies for central nervous system disorders and has partnerships that enhance their research and development efforts.
Read more →PASGPassage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
Passage Bio, Inc. announced that its CEO, William Chou, M.D., will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines Conference on October 2, 2023. The company is focused on developing therapies for central nervous system disorders and has a portfolio addressing both pediatric and adult indications. With collaborations enhancing its capabilities, Passage Bio aims to advance their genetic medicines pipeline effectively.
Read more →PASG▼ -5.1%on this news
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 cont
Passage Bio has reported its financial results for the second quarter of 2023, highlighting significant progress in its clinical programs. The company shared promising interim data from Cohorts 1-4 in the ongoing Imagine-1 clinical trial for GM1 gangliosidosis, boosting confidence in its lead candidate, PBGM01. Financially, they have extended their cash runway into late 2025, allowing continued development efforts in GM1 and frontotemporal dementia programs. The company has also initiated multiple clinical trial sites for its FTD program, suggesting strong ongoing momentum.
Read more →PASG▼ -5.1%on this news
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
Passage Bio announced promising interim results from its Imagine-1 study, focusing on the gene therapy PBGM01 for GM1 gangliosidosis. The data, derived from the first eight patients, demonstrate a favorable safety profile and significant biomarker improvements, including normalization of critical enzyme levels. Additionally, patients treated show early signs of enhanced survival compared to predicted outcomes from historical data. The study is progressing to assess higher dose levels, with the first patient treated at Dose 3 in July 2023, and initial data from this cohort expected in mid-2024.
Read more →PASGPassage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
Passage Bio has appointed Dr. Dolan Sondhi to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Sondhi, a prominent figure in AAV gene therapy with over 20 years of experience, will contribute significantly to Passage Bio's efforts in developing therapies for CNS disorders. Additionally, the company announced the resignation of Thomas Woiwode, Ph.D., to focus on his role at Versant Ventures. This leadership change comes during a pivotal stage for Passage Bio as it advances its clinical programs.
Read more →PASGPassage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
Passage Bio, Inc. (NASDA: PASG) is set to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 12, 2023. The event will feature CEO William Chou discussing the company's mission to develop innovative therapies for central nervous system disorders. Passage Bio is currently advancing several clinical programs and has established a collaboration with the University of Pennsylvania's Gene Therapy Program to support their research efforts.
Read more →PASGPASSAGE BIO REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal
Passage Bio, Inc. has released its financial results for Q1 2023, highlighting its ongoing commitment to developing therapies for CNS disorders. The company is on track to report interim clinical data for its two lead programs, PBGM01 and PBFT02, in the coming months. Efforts to enhance patient recruitment are underway to meet upcoming milestones, though the firm also noted a significant financial loss during the quarter. Passage Bio continues its collaboration with the University of Pennsylvania to support its research and development efforts.
Read more →PASG▲ +5.9%on this news
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
Passage Bio has awarded the second annual Tachi Yamada Scholarship to Nikki Evich, a sophomore at The Pennsylvania State University studying Pharmacology and Toxicology. The scholarship, which honors the legacy of the late Dr. Tachi Yamada, aims to support students pursuing a career in life sciences. Nikki's strong academic performance and passion for neuroscience research were highlighted during the award presentation. The scholarship includes financial assistance and mentorship opportunities over two years.
Read more →PASGPassage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio, a clinical-stage genetic medicines company, announced the granting of an inducement stock option award to a new employee under Nasdaq Listing Rule 5635(c)(4). The company granted options to purchase 82,000 shares at $1.05 each, equal to the stock's closing price on April 17, 2023. The options will vest over four years, promoting employee retention and contributing to the company's mission of developing therapies for central nervous system disorders.
Read more →PASGPassage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Passage Bio, Inc. will have its CEO and CTO participate in a virtual fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023. The event aims to discuss advancements in transformative therapies for central nervous system disorders. The company is making strides in clinical programs for conditions like GM1 gangliosidosis and frontotemporal dementia while collaborating with the University of Pennsylvania's Gene Therapy Program.
Read more →PASGPassage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
Passage Bio, a clinical stage genetic medicines company, will present at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on April 3, 2023. CEO William Chou will participate in a fireside chat at the event held in New York. The company is focused on developing therapies for CNS disorders and has a pipeline that includes programs for GM1 gangliosidosis and frontotemporal dementia, along with collaborations to advance its gene therapy candidates.
Read more →PASGPassage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights Presented additional interim data at 19 th Annual WORLDSymposium showing PBGM01 continued to demonstrate a b
Passage Bio, Inc. reported its financial results for Q4 and the full year 2022 and provided updates on its clinical programs. The company shared positive interim data on PBGM01 for GM1 gangliosidosis, while highlighting enrollment efforts in the upliFT-D trial for frontotemporal dementia. Despite these positives, the company faces financial challenges reflected in an increased net loss. Passage Bio emphasizes its commitment to advancing transformative therapies for CNS disorders with a cash runway into 2025.
Read more →PASGPassage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program
Passage Bio has announced its second annual Tachi Yamada Scholarship program, offering a $10,000 scholarship to a rising junior majoring in life sciences at a Pennsylvania college. The scholarship, which aims to support students aspiring to careers in life sciences, is open for applications until April 1, 2023. The program honors Dr. Tachi Yamada, a co-founder of Passage Bio, emphasizing support for future generations in the industry. Selected scholars will receive mentorship opportunities to foster their professional development during the two-year scholarship period.
Read more →PASGPassage Bio to Present at Cowen 43rd Annual Health Care Conference
Passage Bio, a clinical-stage genetic medicines company, is set to present at the Cowen 43rd Annual Health Care Conference on March 7, 2023. CEO William Chou will participate in a panel discussion focused on orphan neuro diseases. The company is dedicated to developing therapies for CNS disorders, including ongoing clinical programs in GM1 gangliosidosis and frontotemporal dementia. Through a collaboration with the University of Pennsylvania, Passage Bio aims to enhance its gene therapy development.
Read more →PASG▲ +7.7%on this newsshared move
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
Passage Bio, a clinical-stage genetic medicines company, announced it will report its fourth quarter and full-year 2022 financial results on March 6, 2023. The company specializes in therapies for central nervous system disorders and is advancing clinical programs in conditions like GM1 gangliosidosis and frontotemporal dementia. It has also established a strategic collaboration with the University of Pennsylvania for gene therapy innovations.
Read more →PASG▼ -7.9%on this newsshared move
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19 th Annual WORLDSymposium 2023 - Additional interim biomarker and efficacy data from first six patients continue to demonstrat
Passage Bio has presented updated interim data from its Imagine-1 study, featuring the gene therapy PBGM01 for GM1 gangliosidosis, at the 19th Annual WORLDSymposium. The data from the first six patients indicate that PBGM01 is effective in demonstrating biological effects, with MRI severity scores stabilizing and reductions in Dp5 substrate levels. Additionally, the treatment maintained a favorable safety profile. The company anticipates further advancements in the Imagine-1 study and plans to share data from Cohort 4 later this year.
Read more →PASGPassage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
Passage Bio announced it will present updated interim data from the Phase 1/2 Imagine-1 study of PBGM01 for GM1 gangliosidosis at the 19th Annual WORLDSymposium in Orlando. The presentations will cover safety, biomarker, and efficacy data from the study, which involves a novel administration method for this pediatric condition. PBGM01 has received significant designations from the FDA that support its development as a promising gene therapy for a rare genetic disorder with severe consequences. The results may indicate important steps forward in treating this life-threatening condition.
Read more →PASGxA9; 2023 PassageBio. All rights reserved.Nasdaq: PASG Fulfilling the Promise of Genetic Medicine for Central Nervous System DisordersJanuary 2023 2 Forward-Looking StatementThis presentation includes “forward-loo
Passage Bio, listed on Nasdaq under the ticker PASG, is advancing its gene therapy programs aimed at treating severe central nervous system disorders. The company is currently conducting clinical studies for GM1 gangliosidosis and frontotemporal dementia, exploring promising intra-cisterna magna administration methods. With a robust pipeline and a cash balance of $190 million, Passage Bio aims to fulfill its vision of providing transformative therapies for patients with genetic CNS diseases. Initial safety and biomarker data are expected in the second half of 2023.
Read more →PASG▲ +9.6%on this news
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study - Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study PHILADELPHIA, December 14, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies f
Read more →PASG▲ +10.8%on this news· ran to +22% by day 3
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates PHILADELPHIA - November 10, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS)
Read more →PASGPassage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer
Read more →PASGPassage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live web
Read more →PASGPassage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief e
Read more →PASGPassage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Pa
Read more →PASGPassage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employee
Read more →PASGPassage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that the first patient has been dosed in the glo
Read more →PASGPassage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Pas
Read more →PASGPassage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights Philadelphia, PA - August 4, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous s
Read more →PASG▼ -8%on this news
Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live web
Read more →PASGPassage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors
PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Michael Kamarck, Ph.D., to it
Read more →PASGPassage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage B
Read more →PASGPassage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy
• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disord
Read more →PASGPassage Bio Announces Leadership Transition
Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as interim chief executive of
Read more →PASG▲ +10.4%on this news
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees
Read more →PASG▼ -5.3%on this newsshared move
Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25 th Annual Meeting Longer-term follow-up showed continued developmental improvement for both
Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting PHILADELPHIA, May 18, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing tra
Read more →PASG▼ -7.7%on this newsshared move
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interi
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights Philadelphia, PA - May 16, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous syst
Read more →PASG▼ -10.3%on this news· ran to -22% by day 3
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at
Read more →PASGPassage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from
Read more →PASG▲ +5.3%on this news
Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease
Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe disease PBKR03 showed marked improvements in safety, disease progression and key biomarkers for Krabbe disease in
Read more →PASGPassage Bio Provides Update on Strategic Priorities and Extends Cash Runway
Company to reduce workforce and prioritize research and development programs to reduce operating expenses Continued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe disease and frontotemporal dementia Estimated cash runway extended into Q2 2024
Read more →PASGPassage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced that the first patient with early infantile Krabbe di
Read more →PASG▼ -11.6%on this news· ran to -23% by day 3
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights - Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestone
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights Philadelphia, PA - March 3, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for cent
Read more →PASGPassage Bio to Participate in Upcoming March Investor Conferences
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcomin
Read more →PASGPassage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast a
Read more →PASG▼ -9.3%on this news
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLD Symposium - Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium PHILADELPHIA, February 11, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative thera
Read more →PASG▲ +6.8%on this news
Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11 Podium presentations on clinical trial designs for Imagine-1 and GALax-C, the clinical trial for Krabbe disease, Wednesday, February 9
Read more →PASGPassage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline - Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline PHILADELPHIA, January 10, 2022 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous syst
Read more →PASGPassage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Bruce Goldsmith, Ph.D., president, and chie
Read more →PASGPassage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis - Independent Data Monitoring Committee recommends proceeding with two additional planned pati
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis - Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel - P
Read more →PASGPassage Bio Announces Pipeline Expansion and Clinical Program Update
Exercised two additional options with University of Pennsylvania’s Gene Therapy Program aligned with company’s focus on CNS diseases with high unmet need Huntington’s disease, a fatal rare adult neurodegenerative disorder Canavan disease, a fatal rare pediatric leukodystrophy P
Read more →PASGPassage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new empl
Read more →PASGPassage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief execu
Read more →PASGPassage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights - On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights Philadelphia, PA - November 4, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous
Read more →PASGPassage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast a
Read more →PASGFulfilling the Promise of Genetic Medicines for Central Nervous System Disorders Corporate Presentation October 2021 NASDAQ GS: PASG 2 Forward-Looking Statement This presentation includes “forward-looking statemen
Wilson, M.D., Ph.D. Chief Scientific Advisor, Passage Bio Director, Gene Therapy Program Rose H. Weiss Professor and Director, Orphan Disease Center Professor of Medicine and Pediatrics, Department of Medicine Cutting-edge research, expertise, next-generation technologies ~300 fu
Read more →PASGPassage Bio to Participate in Upcoming October Conferences
PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcoming conferences i
Read more →PASGPassage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported that Maxine Gowen, Ph.D., has been appointed cha
Read more →PASGPassage Bio to Present at Citi 16th Annual BioPharma Virtual Conference
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief exec
Read more →PASGPassage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights - Expanded strategic collaboration with University of Pennsylvania's Gene Therapy Program to advance genetic medicines for
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights Philadelphia, PA - August 5, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous
Read more →PASGPassage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, acknowledges today with great sorrow that Tadataka (Tachi) Yamada, M.D
Read more →PASGPassage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president
Read more →PASGPassage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call an
Read more →PASGPassage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it has granted an inducement awa
Read more →PASGPassage Bio Announces Key Executive Appointments
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced three key leadership appointments
Read more →PASGPassage Bio to Participate in Upcoming June Investor Conferences
PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two
Read more →PASGPassage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting
Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy for metachromatic leukodystrophy (MLD) Passage Bio gene therapy candidate, PBM
Read more →PASGPassage Bio to Host Virtual R&D Event on May 17
PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host its second virtual Researc
Read more →PASGPassage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights - Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights Philadelphia, PA - May 5, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervou
Read more →PASGPassage Bio Partners with InformedDNA to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia
No-cost genetic screening and counseling program aimed at identifying FTD patients who have certain inherited genetic mutations to guide early treatment intervention and awareness of clinical trials Passage Bio is evaluating gene therapy candidate, PBFT02, for treatment of FTD w
Read more →PASGPassage Bio to Report First Quarter 2021 Financial Results on May 5, 2021
PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast
Read more →PASGPassage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease
- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options - Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 - Global Phase 1/2 trial – GALax-C – PBKR03 planned
Read more →PASGPassage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company – PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative
Read more →PASGPassage Bio to Participate in Upcoming April Investor Conferences
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming v
Read more →PASGPassage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc,
Read more →PASGPassage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights - On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Philadelphia, PA - March 3, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders
Read more →PASGPassage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021
PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast
Read more →PASGPassage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its
Read more →PASGPassage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifyin
Read more →PASGPassage Bio Announces Pricing of Public Offering
PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced the pricing of its underwritten public offering of 7,0
Read more →PASGPassage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Developme
Read more →PASGPassage Bio Announces Launch of Proposed Public Offering
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced that it has commenced an underwritten public offering
Read more →PASGPassage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021 - Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 fo
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021 - Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease - - Three clinical programs to begin in
Read more →PASGPassage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief exec
Read more →PASGPassage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021 PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on
Read more →PASGPassage Bio Announces Gene Therapy Manufacturing Research and Development Site
- Company invests to build in-house capabilities to support advancement of pipeline - - In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV gene therapy manufacturing - PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Pa
Read more →PASGPassage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - Patient enrollment in UK clinical study site expected to start in the second quarter of 2021 - PHILADELPHIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasda
Read more →PASGPassage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products
PHILADELPHIA and SOMERSET, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, and Catalent, the leading global provider of
Read more →PASGPassage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., chief executive officer
Read more →PASGPassage Bio to Participate in Upcoming November Investor Conferences
PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virt
Read more →PASGPassage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy
PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today commends the newly published research of the University o
Read more →PASGPassage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights - Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021
Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights - Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 - - Phase 1/2 clinical trials for FTD-GRN and Krabbe expe
Read more →PASGPassage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announc
Read more →PASGPassage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast
Read more →PASGPassage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →PASGPassage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis
PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the European Commission (EC) has granted orphan
Read more →PASGPassage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic
PHILADELPHIA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced publication of data in a murine model of GM1 ganglios
Read more →PASGPassage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa
PHILADELPHIA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in the virtual 2020
Read more →PASGPassage Bio to Participate in Upcoming October Investor Conferences
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming vir
Read more →PASGPassage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
Data Show Single Injection of AAV-Granulin Gene Therapy into Central Nervous System Reverses Frontotemporal Dementia Pathology Caused by Granulin Mutations and is Well Tolerated Study Conducted by the University of Pennsylvania’s Gene Therapy Program Supports Further Developmen
Read more →PASGCorporate Presentation SEPTEMBER 2020 Forward - Looking Statements This presentation includes "forward - looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securiti
Corporate Presentation SEPTEMBER 2020 Forward - Looking Statements This presentation includes "forward - looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995 , including, but not limit
Read more →PASGPassage Bio to Participate in Citi’s 15th Annual BioPharma Virtual Conference
PHILADELPHIA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in Citi’s 15th Annu
Read more →PASGPassage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights - Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery devic
Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery Anticipate dosing first patient in PBGM01 Phase 1/2 trial in late 4Q2020
Read more →PASGPassage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
PHILADELPHIA, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast
Read more →PASGPassage Bio Added to Russell 2000 Index
PHILADELPHIA, June 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it has been added to the Russell 2000® Index, ef
Read more →PASGPassage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference
PHILADELPHIA, June 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in a fireside chat a
Read more →PASGPassage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis
PHILADELPHIA, May 21, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the U.S. Food and Drug Administration (FDA) has grante
Read more →PASGPassage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
– Preclinical data from University of Pennsylvania’s Gene Therapy Program demonstrate single injection of AAVhu68 carrying a functional GALC gene resulted in normalization of GALC enzyme activity and improved all parameters in animal models of Krabbe disease – – Treated Krabbe d
Read more →PASGPassage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights - Expansion of gene therapy collaboration with University of Pennsylvania's Gene Therapy Program extends collaboration by three addi
Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights therapy collaboration with University of Pennsylvania's Gene Therapy Program extends collaboration by three additional years and adds five new programs - - Orphan Drug Designation recently granted
Read more →PASGPassage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
Option to license an additional five programs for a total of seventeen Extended option and research term to allow for collaboration through 2025 Exclusive rights to certain technologies resulting from GTP’s gene therapy research PHILADELPHIA, May 07, 2020 (GLOBE NEWSWIRE) -- P
Read more →PASGPassage Bio to Report First Quarter 2020 Financial Results on May 11, 2020
PHILADELPHIA, May 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast a
Read more →PASGPassage Bio to Present at 19th Annual Needham Healthcare Conference
PHILADELPHIA, April 08, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will present at the virtual 19th Ann
Read more →PASGPassage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in the virtual Gugg
Read more →PASGPassage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
PHILADELPHIA, March 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced that t
Read more →PASGPassage Bio Appoints Athena Countouriotis to Board of Directors
PHILADELPHIA, March 05, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Athena Countouriotis to its board of di
Read more →PASGPassage Bio Announces Pricing of Initial Public Offering
PHILADELPHIA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the pricing of its ini
Read more →PASGPassage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer
PHILADELPHIA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the appointment of Bruce Gol
Read more →PASGPassage Bio Appoints Sandip Kapadia to Board of Directors
PHILADELPHIA, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced the appointment of Sandip Kapadia to its board of directors. Mr. Kapadia is
Read more →PASGPassage Bio to Present at Piper Jaffray 31st Annual Healthcare Conference
PHILADELPHIA, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Co
Read more →PASGPassage Bio to Present at Barclays Gene Editing & Gene Therapy Summit
PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, chief operating officer, will present at the Ba
Read more →PASGPassage Bio Appoints Richard Morris as Chief Financial Officer
PHILADELPHIA, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointment of Richard Morris as chief financial officer. “We
Read more →PASGPassage Bio to Present at Upcoming Investor Conferences
PHILADELPHIA, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that management will present at three investor conferences in Oct
Read more →PASGPassage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments
PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointments of Gary Romano, M.D., Ph.D, as chief medical off
Read more →PASGPassage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A
PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced that it has licensed a sixth gene therapy development progr
Read more →PASGPassage Bio Closes $110 Million Series B Financing
PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced the closing of a $110.0 million Series B financing. The fin
Read more →PASGPassage Bio to Present at Morgan Stanley 17th Annual Global Healthcare Conference
PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, Chief Operating Officer, will present at the M
Read more →PASGPassage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 Gangliosidosis
PHILADELPHIA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the launch of a Natural History Study to evaluate patients with Ty
Read more →PASGPassage Bio to Present at 2019 Wedbush PacGrow Healthcare Conference
PHILADELPHIA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Dr. Stephen Squinto, interim Chief Executive Officer, will pr
Read more →PASGPassage Bio Expands Executive Management Team
PHILADELPHIA, July 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the expansion of the Company’s executive management team. Jill Qui
Read more →PASGPassage Bio Announces New Dedicated Gene Therapy Manufacturing Suite
PHILADELPHIA, July 10, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that it has entered into a collaboration agreement with Paragon Ge
Read more →PASGPassage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala
PHILADELPHIA, May 30, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that its third clinical trial program will be for infantile Krabbe
Read more →PASGPassage Bio to Present at Jefferies 2019 Healthcare Conference
PHILADELPHIA, May 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, J.D., Chief Operating Officer & General Counsel, w
Read more →PASGPassage Bio Appoints Saqib Islam to Board of Directors
PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases, today announced the appointment of Saqib Islam to its Board of Directors. Mr. Islam
Read more →PASGPassage Bio to Present at the Cowen and Company 39th Annual Health Care Conference
PHILADELPHIA, March 05, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases, today announced that Stephen Squinto, Ph.D., co-founder and interim chief executive
Read more →PASGPassage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures. The funding wil
Read more →Competitive Position
How PASG ranks across every disease it competes inCompetitive Position is a premium feature
See how PASG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial